Arch Oncology, Inc., a clinical-stage immuno-oncology company focused on the discovery and development of anti-CD47 biologic therapies, today announced that the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation to AO-176 on January 3rd, 2022, for the treatment of relapsed/refractory multiple myeloma (r/r MM). AO-176, the Company’s next-generation anti-CD47 antibody, is highly differentiated, with the potential for an improved safety and efficacy profile relative to other agents in this class…
